RNAi Therapeutics Market Report 2023: Growth Opportunities and Major Key Company Profiles: USD Analytics

RNAi Therapeutics Market Report 2023: Growth Opportunities and Major Key Company Profiles: USD Analytics
USD Analytics
One of the major drivers of the RNAi therapeutics market is the growing demand for targeted and personalized therapies. RNA interference (RNAi) technology offers a unique approach to treating various diseases by selectively silencing disease-causing genes. This targeted therapy approach has the potential to address diseases that were previously considered difficult to treat, such as genetic disorders, viral infections, and certain types of cancers.

RNAi Therapeutics Market Overview:

According to the USD Analytics published latest research report, the global “RNAi Therapeutics Market” is expected to grow at a tremendous CAGR of 10.12% during the forecast period 2023-2030.

RNAi refers to interference RNA, which controls and manipulates protein translation in the cell. These RNAi are used to quiet specific genes that cause illnesses. RNAi is gaining popularity owing to its potential to provide a target-specific mechanism, resulting in higher therapy results. The method is commonly used in drug development. Increasing investments in RNAi treatment development and an increase in the frequency of infectious illnesses and chronic ailments are expected to fuel the growth of the RNAi Therapeutics market during the projected period.

Browse Full Report Description @ https://www.usdanalytics.com/industry-reports/rnai-therapeutics-market

Market Drivers:

Cancer diagnosis and treatment are currently undergoing a shift with the incorporation of RNAi techniques in personalized medicine and molecular diagnostics. Because of the availability of high throughput methods for identifying changed cellular components and metabolites, RNAi techniques may be used in various cancer detection and targeting approaches. According to the article titled ‘Insight into the Prospects for RNAi Therapy of Cancer’ published in March 2021, RNAi knocks down the expression of target genes, locating these nodes that are essential to tumor maintenance, with low side effects and risk, blocking the inherent immunosuppression and triggering immune attacks on tumors.

Furthermore, one of the benefits of RNAi technology is the quick creation of effective and tailored medications for tumor growth control. Small interfering RNAs (siRNA) or microRNAs (miRNA) may be used for diagnostic reasons. The commercial availability of siRNAs that can silence practically any gene in the human genome hastened molecular diagnostics and biomedical research. Thus, expanding the use of RNAi in molecular diagnostics and its potential as a therapeutic tool may drive the RNAi industry forward.

Market Restraints:

Drug approval rates at the FDA have been falling in recent years. Getting FDA clearance for a novel medicine is becoming more complicated. In 2020, it authorized less than half as many new medications. Consequently, despite significant expenditure, the number of novel pharmaceuticals produced has fallen. The FDA attributes this decreased tendency to manufacturing standards and other compliance difficulties. This might hinder the progress of RNAi therapies, mainly since miRNAs and siRNAs come within the relatively new discipline of genetic medicine, which may demand more expensive clinical studies.

Market Opportunities:

The increasing use of RNAi therapies for treating neurodegenerative illnesses is projected to open new business possibilities. Silence Therapeutics’ mRNA GOLD platform, for example, delivers gene-silencing therapy to particular liver cells in the body by mixing siRNA molecules with GaINAc. This naturally occurring sugar binds selectively to liver cells. These RNA interference molecules may then infiltrate liver cells and silence disease-related genes that are expressed there.

Covid-19 Impact Analysis:

COVID-19 is likely to have a substantial influence on market growth. RNA interference in developing COVID-19 disease therapies is expected to boost demand. According to the article titled ‘Prospects for RNAi Therapy of COVID-19’ published in July 2020, RNAi against COVID-19 disease can potentially be directed against two different categories of targets: viral proteins essential for SARS-CoV-2 survival and replication and host factors involved in virus cellular entry and trafficking. The potential advantages of RNA interference in developing COVID-19 treatment are predicted to boost market expansion.

Download Sample Report along with Table of Content @ https://www.usdanalytics.com/sample-request/7419

Recent Industry Developments:

  1. Sirnaomics Lts began Phase one clinical research in the United States in February 2022 to evaluate the safety, tolerability, and anti-tumor effectiveness of the company’s siRNA (Small interfering RNA) therapeutic candidate, STP707, using intravenous (IV) dosing.
  2. Novartis gained FDA clearance for Leqvio, a small interfering RNA (siRNA) treatment for low-density lipoprotein with two doses per year following an initial dosage and one at three months, in December 2021.
  3. OliX Pharmaceuticals and LGC Biosarch Technology agreed in June 2020 to accelerate the production of asymmetric siRNA to treat wet macular degeneration and subretinal fibrosis.

RNAi Therapeutics Market Segmentation Analysis:

As per the research an analysis, the global RNAi therapeutics market is segmented by application into drug discovery and development therapeutics into oncology, ocular disorders, respiratory disorders, hepatitis B and C, autoimmune hepatitis, neurological disorders, and other therapeutics.

The Oncology Segment is Expected to Hold a Significant Market Share During the Forecast Period.

The rising prevalence of cancer in the worldwide population, boosting demand for effective therapies, is likely to fuel the expansion of the studied category. According to the International Agency for Research on Cancer’s GLOBOCAN 2020 study, there will be an estimated 19,292,789 new instances of cancer identified in 2020, with an estimated 9,958,133 individuals dying from cancer worldwide. According to the same source, of the total diagnosed cancer cases, 10,065,305 were recorded in men and 9,227,484 in females. Male cancer cases were anticipated to reach 15,585,096 by 2040, while female cancer cases were expected to reach 13,302,846 by 2040. The growing prevalence of cancer among the worldwide population is likely to fuel market expansion.

Avail Discount @ https://www.usdanalytics.com/discount-request/7419

Geographical Analysis:

The global RNAi therapeutics market is segmented into North America, Europe, South America, Asia Pacific, and Middle East & Africa.

North America RNAi Therapeutics Market

North America is likely to create profitable prospects for market expansion because of the increased frequency of target illnesses and expanding demand for sophisticated therapies and diagnostics. According to the American Cancer Society, about 1.9 million new cancer cases are predicted to be diagnosed in the United States in 2022. Furthermore, 80% of patients diagnosed with cancer in the United States are 55 or older, with 57% being 65 or older. As a result of the high frequency of cancer and the growing afflicted elderly population, the country’s need for diagnostics and treatment is also significant, which is likely to fuel expansion in the analyzed market in the United States.

Asia-Pacific RNAi Therapeutics Market

Asia-Pacific is predicted to develop at the fastest pace over the forecast period due to increased health awareness and demand for improved medical technology.

Download Sample Report along with Table of Content @ https://www.usdanalytics.com/sample-request/7419

Competitive Landscape:

The major companies included in the global RNAi therapeutics market are Alnylam Pharmaceuticals, Arrowhead, Dicerna Pharmaceuticals (Novo Nordisk A/S), Thermofisher Scientific, Silence Therapeutics PLC.

Media Contact
Company Name: USD Analytics
Contact Person: Harry James
Email: Send Email
Country: India
Website: https://www.usdanalytics.com/industry-reports/rnai-therapeutics-market